Halozyme Therapeutics HALO Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $376.71M-16.6% | $451.77M+27.5% | $354.26M+8.8% | $325.72M+23.0% | $264.86M-11.1% | ||
| $79.24M+0.6% | $78.77M+42.6% | $55.24M+19.2% | $46.36M-4.2% | $48.4M+15.1% | ||
| $297.47M-20.2% | $373M+24.7% | $299.02M+7.0% | $279.36M+29.1% | $216.46M-15.4% | ||
| 79%-3.6pp | 82.6%-1.8pp | 84.4%-1.4pp | 85.8%+4.0pp | 81.7%-4.2pp | ||
| $25.56M-19.9% | $31.9M+84.9% | $17.25M-1.7% | $17.54M+18.5% | $14.8M-27.6% | ||
| $57.88M-24.9% | $77.03M+67.1% | $46.09M+10.8% | $41.61M-1.8% | $42.36M+0.3% | ||
| $192.19M-64.7% | $544.66M+299% | $136.34M+10.6% | $123.28M0.0% | $123.33M+0.7% | ||
| $184.52M— | —— | $217.92M+7.6% | $202.44M+43.0% | $141.54M-19.4% | ||
| 49%— | —— | 61.5%-0.6pp | 62.2%+8.7pp | 53.4%-5.5pp | ||
| $5.51M+12.2% | $4.91M+14.3% | $4.3M-2.2% | $4.39M-2.9% | $4.53M-0.3% | ||
| $1.32M-45.8% | $2.43M-54.4% | $5.33M-22.6% | $6.89M+1.1% | $6.82M-6.0% | ||
| $180.33M— | —— | $218.96M+6.8% | $204.94M+42.5% | $143.83M-19.3% | ||
| $30.28M-25.7% | $40.74M-6.8% | $43.73M+9.9% | $39.78M+54.6% | $25.73M-37.5% | ||
| $150.05M— | —— | $175.23M+6.1% | $165.16M+39.9% | $118.1M-13.8% | ||
| 39.8%— | —— | 49.5%-1.2pp | 50.7%+6.1pp | 44.6%-1.4pp | ||
| $1.22— | —— | $1.43+7.5% | $1.33+43.0% | $0.93-12.3% | ||
| $188.74M— | —— | $220.62M+7.5% | $205.14M+42.2% | $144.22M-19.0% | ||
| 50.1%— | —— | 62.3%-0.7pp | 63%+8.5pp | 54.5%-5.3pp | ||
| $184.52M— | —— | $217.92M+7.6% | $202.44M+43.0% | $141.54M-19.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Halozyme Therapeutics's revenue?
- Halozyme Therapeutics (HALO) generated $1.5B in revenue over the trailing twelve months, up 39.1% year over year.
- Is Halozyme Therapeutics profitable?
- Halozyme Therapeutics reported $608.5M in net income over the trailing twelve months, a 47.9% net margin.
- What are Halozyme Therapeutics's profit margins?
- Gross margin is 82.8% and operating margin is 59.3%, with a 47.9% net margin.
- What is Halozyme Therapeutics's earnings per share?
- Halozyme Therapeutics's diluted EPS over the trailing twelve months is $4.91.
- Where does Halozyme Therapeutics's income statement data come from?
- Every line is extracted from Halozyme Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
